Business Context and Reporting Period
This Form 8-K Current Report, filed on February 22, 2024, by Madrigal Pharmaceuticals, Inc. (MDGL), discloses significant changes to the company's executive leadership team. The report details the appointment of a new Chief Financial Officer and the departure of two senior officers, effective in March and May 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment arrangements.
Material Changes
Appointment of New CFO
- Mardi C. Dier was appointed Senior Vice President and Chief Financial Officer, effective March 11, 2024.
- Ms. Dier joined as a Senior Advisor on February 27, 2024, prior to assuming the CFO role.
- Compensation Package:
- Annual base salary: $550,000.
- Target annual performance bonus: 45% of base salary.
- Monthly living expense stipend: Up to $7,000 for the first year.
- Initial equity award: Target aggregate value of $6.7 million (split equally among time-based RSUs, stock options, and performance stock units).
Departure of Former CFO
- Alex G. Howarth is stepping down as CFO to be replaced by Ms. Dier.
- Mr. Howarth will remain as a Senior Advisor through May 31, 2024, to ensure a smooth transition.
- Separation Benefits (if terminated without cause):
- 12 months of base salary and target bonus, paid in monthly installments.
- Accelerated vesting of equity awards that would have vested over the subsequent 12 months.
- 12 months of health benefits continuation.
- The departure involves no disagreement regarding accounting policies or internal controls.
Departure of General Counsel
- Brian J. Lynch, Senior Vice President and General Counsel, is departing after a transition period expected to conclude on May 31, 2024.
- Mr. Lynch will receive separation benefits identical in structure to Mr. Howarth's (12 months salary/bonus, accelerated equity vesting, and health benefits) if terminated without cause.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of business risks. The primary contingency noted is the execution of general releases of claims by departing officers to receive their severance benefits. The company has entered into a Severance and Change of Control Agreement with Ms. Dier, which includes specific provisions for termination without cause or for good reason, as well as change of control scenarios.
Investor Verification Checklist
- Verify the effective date of Mardi C. Dier's assumption of duties as CFO (March 11, 2024).
- Confirm the total value and vesting schedule of the $6.7 million initial equity award granted to Ms. Dier.
- Review the specific terms of the "Qualifying Separation" and "Change of Control" definitions in the new Severance and Change of Control Agreement.
- Monitor the transition period ending May 31, 2024, for the departure of Alex G. Howarth and Brian J. Lynch.
- Check for any subsequent filings regarding the appointment of a successor to Brian J. Lynch as General Counsel.